Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease

Rheumatology (United Kingdom)

Volumn 55, Issue 1, 2016, Pages 103-108

  Gunnarsson, Ragnar ^a   El Hage, Fadi ^b   Aaløkken, Trond Mogens ^a   Reiseter, Silje ^c   Lund, May Brit ^a,c   Garen, Torhild ^a   Molberg, Oyvind ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

anti La; Anti Ro; Anti SSA Ro52; Anti SSA Ro60; Interstitial pulmonary fibrosis; Lung diseases; Mixed connective tissue disease; Scleroderma systemic; Sj gren's syndrome; SSB antigen

Indexed keywords

RO ANTIBODY; RO52 ANTIBODY; RO60 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY SCREENING; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 84960122973     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev300     Document Type: Article

References (19)

1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59.
2. Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 2005;31:411-20.
3. Sharp GC, Irvin WS, May CM et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976;295:1149-54.
4. Gunnarsson R, Andreassen AK, Molberg Ø et al. Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology 2013;52:1208-13.
5. Burdt MA, Hoffman RW, Deutscher SL et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999;42:899-909.
6. Gunnarsson R, Aaløkken TM, Molberg Ø et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 2012;71:1966-72.
7. Saito Y, Terada M, Takada T et al. Pulmonary involvement in mixed connective tissue disease: comparison with other collagen vascular diseases using high resolution CT. J Comput Assist Tomogr 2002;26:349-57.
8. Hudson M, Pope J, Mahler M et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 2012;14:R50.
9. Marie I, Hatron PY, Dominique S et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012;41:890-9.
10. Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C. Anti-Ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol 2012;2012:415272.
11. Setty YN, Pittman CB, Mahale AS, Greidinger EL, Hoffman RW. Sicca symptoms and anti-SSA/Ro antibodies are common in mixed connective tissue disease. J Rheumatol 2002;29:487-9.
12. Gunnarsson R, Molberg O, Gilboe IM, Gran JT, PAHNOR1 Study Group. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis 2011;70:1047-51.
13. Sharp GC. Diagnostic criteria for classification of MCTD. In: Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division), 1987, 23-30.
14. Alarcón-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Amsterdam: Elsvier Science Publishers B.V. (Biomedical Division), 1987, 33-40.
15. Kasukawa R, Tojo T, Miyawaki S et al. Prelimary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division), 1987, 41-7.
16. Austin JH, Müller NL, Friedman PJ et al. Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society. Radiology 1996;200:327-31.
17. Hansell DM, Bankier AA, MacMahon H et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246:697-722.
18. Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
19. Distler JHW, Strapatsas T, Huscher D et al. Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Ann Rheum Dis 2011;70:1197-202.